Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

计划入组 48 人 · 首次发布于 2022 年 1 月 12 日

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

计划入组 34 人 · 首次发布于 2025 年 2 月 5 日

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

计划入组 60 人 · 首次发布于 2025 年 7 月 31 日

Bifunctional PD-L1-Targeted Sialidase

Anti-VEGF/PD-1 bispecific antibody (Biox-Vision)

PD-1 monoclonal antibody

Cambridge Antibody Technology

New Zealand

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

NAYA Biosciences Expands Oncology Pipeline with Novel PD-1 x VEGF Antibody

Crescent Biopharma Advances PD-1 x VEGF Bispecific Antibody CR-001 Toward Phase 1 Trial

BioNTech's VEGF x PD-L1 Bispecific BNT327 Shows Promise in TNBC